Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Operating activities
Net loss	$ (31,333)	$ (40,455)	$ (29,524)	$ 61,022	$ (84,513)	$ (30,427)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Non-cash loss on extinguishment of debt	0		0		0	53,235
Non-cash royalty revenue					(40,420)	(16,391)
Paid-in-kind interest on long-term debt					8,986	0
Depreciation expense					79	36
Amortization of debt issuance costs and discounts					2,366	1,326
Non-cash interest expense related to the revenue interest liability					0	21,569
Non-cash interest expense related to the royalty sale liability					41,000	11,984
Stock-based compensation expense					7,483	9,188
Changes in assets and liabilities:
Accounts receivable					(38,838)	(19,330)
Prepaids and other assets					(21,894)	(10,212)
Deferred revenue					22,161	(10,324)
Inventories					(14,048)	(14,479)
Other long-term liabilities					7,436	0
Accounts payable					33,363	3,128
Other accrued liabilities					18,503	11,995
Net cash (used in) provided by operating activities					(58,336)	11,298
Investing activities
Purchase of property and equipment					0	(317)
Net cash (used in) investing activities					0	(317)
Financing activities
Payments on revenue interest liability					0	(5,832)
Repurchase of revenue interest liability					0	(343,750)
Payment of royalty sale liability issuance costs					0	(9,626)
Proceeds from royalty sale liability					0	304,656
Proceeds from issuance of common stock, net of issuance costs					0	90,672
Proceeds from issuance of common stock from ATM program, net of issuance costs					13,381	531
Proceeds from exercise of common stock options					141	29
Proceeds from exercise of warrants, net of issuance costs					0	14,808
Payment of issuance costs					(7,500)	0
Net cash provided by financing activities					6,022	51,488
Net (decrease) increase in cash and cash equivalents					(52,314)	62,469
Cash and cash equivalents at beginning of period		$ 144,761		$ 82,248	144,761	82,248	$ 82,248
Cash and cash equivalents at end of period	$ 92,447		$ 144,717		92,447	144,717	$ 144,761
Supplemental disclosure of cash flow information:
Common stock issuance costs not yet paid					103	18
Non-cash right of use asset					$ 29	$ 80